ArticleJournal of neuroendovascular therapy2026
Transarterial Embolization for Medically Refractory Kasabach-Merritt Syndrome: A Case Report.
Article in Journal of neuroendovascular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Kasabach-Merritt syndrome (KMS) is a life-threatening disorder characterized by severe thrombocytopenia and consumptive coagulopathy associated with vascular tumors, typically Kaposiform hemangioendothelioma (KHE) or tufted angioma. Drug therapy is the first-line treatment, but some cases are refractory, and no established salvage therapy exists. This report describes a case of KMS resistant to multiple drug therapies in which transarterial embolization (TAE) was successfully performed. Case Presentation: A 2-month-old male infant presented with a left posterior neck mass. Examination revealed severe thrombocytopenia (5000/μL) and coagulation abnormalities. Imaging studies diagnosed KMS with KHE. Platelet counts did not improve despite sequential treatment with corticosteroids, beta-blockers, and sirolimus. TAE was indicated due to the high risk of fatal bleeding. Angiography identified feeding vessels from the posterior muscular branch of the vertebral artery and the ascending cervical artery. TAE was performed using 20% n-butyl-2-cyanoacrylate (NBCA) for the vertebral artery branch and gelatin sponge particles for the ascending cervical artery branch. Post-embolization, platelet counts normalized, and the tumor shrank. Conclusion: In a case of drug-resistant KMS, TAE effectively restored platelet counts and prevented fatal complications. When performed with appropriate embolic selection and careful complication management, arterial embolization can be a useful adjunctive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.